OHM Investment Corporation bought 3,14,939 shares of Panacea Biotec at ₹493.07, a stake of about 0.51%, for roughly ₹15.52 crore. That matters because Panacea is still a tightly held stock, with promoters at 72.48% and only small institutional ownership in the public float, so even a half-percent stake purchase is meaningful in ownership terms. The buyer is not a random entity either: OHM sits inside the Ohm Stock Broker / OHM group, a long-running Indian capital-markets platform founded in 1999, and its PMS arm, OHM Portfolio Equity Research, has public SEBI disclosures showing over ₹600 crore of equity AUM. In other words, this is a professional money manager.
The deal also sits in a sensible price context. Panacea was trading around the low-to-mid ₹400s in recent sessions and had been moving closer to its 52-week high, so the buyer was not trying to catch a collapsing stock; it stepped in while sentiment was already improving. That usually makes the signal stronger, because it suggests conviction rather than bargain hunting after distress.
The main takeaway is that this is a positive institutional-quality buy in a promoter-heavy, under-owned stock. It does not automatically mean the stock will rerate, but it does tell you that a serious domestic capital-market participant was willing to commit meaningful money at around ₹493, which is exactly the kind of behavior worth tracking in a stock like Panacea.
Leave a Reply